3 Radiopharmaceutical / Radioligand CRO and CDMO vendors

What does it take to develop and manufacture a Radiopharmaceutical / Radioligand drug?

Radiopharmaceuticals are two molecules doing one job: a targeting ligand (a small molecule, peptide, or antibody) bonded through a chelator or covalent linker to a radioactive isotope that either images disease or kills the cell it lands on. That second half is what makes this modality unlike anything else you will outsource. The product is radioactive, it is decaying from the moment it is made, and a lot of your development timeline is governed by a half-life rather than a Gantt chart. A Lu-177 therapy gives you days of working window; a Ga-68 or F-18 PET tracer gives you hours. Ac-225 and other alpha emitters add their own handling and daughter-isotope headaches. None of that is negotiable, and it shapes every vendor decision downstream.

On the discovery and preclinical side the work looks partly familiar and partly specialized. You need medicinal chemistry to build and optimize the targeting vector, then chelator chemistry (DOTA, DOTAGA, NOTA, and the rest) or site-specific conjugation to attach the payload without wrecking binding affinity. Then comes radiolabeling chemistry, where the team works out labeling conditions, radiochemical yield, and radiochemical purity, and biodistribution and dosimetry studies in animals to see where the activity goes and how much hits off-target tissue (kidney and bone marrow uptake are the usual worries). Autoradiography, SPECT/PET imaging, and a real understanding of theranostic pairing, using the same vector with a diagnostic isotope to image and a therapeutic isotope to treat, separate teams who have done this from teams reading about it.

CMC and manufacturing is where generalist CDMOs fall away. You cannot make this product in an ordinary fill-finish suite. Radiopharma manufacturing happens in shielded hot cells and isolators, behind lead, often with automated synthesis modules so operators are not standing next to the activity. The site has to hold a radioactive materials license (NRC or an Agreement State, equivalent abroad) on top of GMP, run radiation safety and ALARA programs, and manage radioactive waste. Then there is the QC problem that defines the whole field: you have to complete sterility-relevant and identity, radiochemical purity, and radionuclidic purity testing and release the batch before it decays below a usable dose, so analytical methods are validated for speed as much as accuracy, and some release happens on a rapid or parametric basis with confirmatory testing after the dose has already shipped. Specialist radiopharmaceutical CDMOs are built around isotope supply contracts, decentralized or centralized dose production near the clinic, and cold-chain-plus-decay logistics. A generalist simply is not set up for any of it.

How do you choose a CRO or CDMO for Radiopharmaceutical / Radioligand?

Vendor fit in this modality is narrower than almost any other, because the equipment, licenses, and isotope relationships take years to build and cannot be improvised for your project. Work through this checklist before you shortlist, and weight isotope access and licensing heavily: a brilliant radiochemistry team with no reliable supply of your isotope cannot run your program.

• Relevant platform and track record: have they actually labeled and released your isotope class (Lu-177, Ac-225, I-131, Ga-68, F-18, Cu-64, others), with the specific chelator or conjugation chemistry your vector uses? Ask for programs they have taken from labeling development through GMP batches.
• Isotope supply and sourcing: where do they get the isotope, is the supply contracted and redundant, and can they meet your dose schedule given the half-life? Sole-source isotope risk has stalled real programs, so this question comes first, not last.
• GxP and analytical capability for this modality: shielded hot cells or isolators, automated synthesis modules, radiation-licensed GMP site, plus QC methods validated for radiochemical purity, radionuclidic purity, and rapid release on a decay clock. Confirm sterility approach for a product you cannot fully test before shipping.
• Regulatory experience: a documented history with radiopharmaceutical INDs and NDAs, dosimetry packages, and the radiation safety and licensing layer that sits on top of normal GMP. Experience with theranostic pairing filings is a plus if that is your strategy.
• Capacity and scale: can they go from a handful of preclinical labelings to clinical doses to commercial supply without you re-qualifying a new site mid-program? Ask about batch frequency, hot-cell availability, and whether they run decentralized production near trial sites.
• Dosimetry and preclinical depth (if sourcing earlier work): biodistribution, dosimetry modeling, autoradiography, and imaging readouts that will actually support your IND, not just internal data.
• IP, confidentiality, and freedom to operate: clear ownership of labeling methods and process know-how, watertight confidentiality given how small and interconnected this field is, and a check that their chelator or linker chemistry does not drag in third-party IP.